# Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation

> **NCT06187311** · PHASE4 · RECRUITING · sponsor: **Korea University Anam Hospital** · enrollment: 940 (estimated)

## Conditions studied

- Atrial Fibrillation
- Anticoagulant Adverse Reaction

## Interventions

- **DRUG:** Rivaroxaban 20 MG
- **DRUG:** Rivaroxaban 15 MG

## Key facts

- **NCT ID:** NCT06187311
- **Lead sponsor:** Korea University Anam Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-12
- **Primary completion:** 2026-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 940 (ESTIMATED)
- **Last updated:** 2024-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06187311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06187311, "Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06187311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*